ADC Therapeutics reweighs ZYNLONTA path after FDA raises LOTIS-5 safety concerns
The company posted $18.6 million in Q2 2026 product revenue and $219.1 million in cash while evaluating next steps after an FDA pre-sBLA meeting flagged benefit-risk issues in the LOTIS-5 trial.
SEC filing